SINOPHARM (01099) has released financial results for its subsidiary, China National Medical Device Co., Ltd., for the three-month period ended March 31, 2026. The subsidiary reported operating revenue of approximately 17 billion yuan, representing a 1.23% year-on-year increase. However, operating profit stood at 220 million yuan, a decrease of 20.41% compared to the same period last year. Comprehensive income attributable to owners of the parent company was 115 million yuan, down 7.47% year-on-year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments